Synedgen
Claremont, US · Founded 2009 · Delaware corporation
Synedgen develops first-in-class glycomics-based regenerative therapeutics that repair mucosal injury and restore barrier function. Its lead asset, MIIST305, is an orally delivered therapeutic that repairs gastrointestinal mucosal injury and reduces inflammation.
Founders & leadership
Synedgen was founded in 2009 by Shenda Baker and William P. Wiesmann.
SB
Shenda BakerinCo-founder
WP
William P. WiesmanninCo-founder
KP
Kaveri ParkerinExecutive
LS
Laura SawardinChief Executive Officer
Board
PC
Paul C. GrintBoard director
HO
Hal OienBoard director
AW
Andrew W. MillerBoard director
DB
Daniel BradburyBoard director
KG
Kenton GregoryChief Medical Officer
CA
Clarke AtwellBoard director
LS
Larry ShapiroBoard director
DO
Diane OlmsteadBoard director
Reported raises · per SEC filings
Form D private placements$20.4M disclosed across 7 rounds · 2014–2024
▶$1.8MraisedOct 2024 · 4 investors · PharmaceuticalsRule 506(b)
▶$1.8MraisedOct 2024 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Shenda BakerExecutive Officer, Director
- William P. WiesmannExecutive Officer, Director
- Paul C. GrintDirector
- Hal OienDirector
- Andrew W. MillerDirector
- Daniel BradburyDirector
- Kaveri ParkerExecutive Officer
- Kenton GregoryDirector
- Offering amount
- $2M
- Amount sold
- $1.8M
- Proceeds to insiders
- $465K
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.5MraisedJul 2019 · 1 investors · PharmaceuticalsRule 506(b)
▶$2.5MraisedJul 2019 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Shenda BakerExecutive Officer, Director
- William P. Wiesmann, M.D.Executive Officer, Director
- Kenton Gregory, M.D.Director
- Paul Grint, M.D.Director
- Andrew W. MillerDirector
- Offering amount
- $3M
- Amount sold
- $2.5M
- First sale
- Jun 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedSep 2017 · 3 investors · PharmaceuticalsRule 506(b)
▶$3MraisedSep 2017 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Kenton Gregory, M.D.Director
- Shenda BakerExecutive Officer, Director
- William P. Wiesmann, M.D.Executive Officer, Director
- Robert CoughlinDirector
- Andrew W. MillerDirector
- Paul Grint, M.D.Director
- Offering amount
- $3M
- Amount sold
- $3M
- First sale
- Aug 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedNov 2016 · 1 investors · PharmaceuticalsRule 506(b)
▶$3MraisedNov 2016 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Kenton GregoryDirector
- Paul GrintDirector
- Robert CoughlinDirector
- William WeismannExecutive Officer, Director
- Larry ShapiroDirector
- Andrew MillerDirector
- Shenda BakerExecutive Officer, Director
- Offering amount
- $3.5M
- Amount sold
- $3M
- First sale
- Oct 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6MraisedApr 2016 · 1 investors · PharmaceuticalsRule 506(b)
▶$6MraisedApr 2016 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Paul GrintDirector
- Shenda BakerExecutive Officer, Director
- Kenton GregoryDirector
- Larry ShapiroDirector
- Clarke AtwellDirector
- Diane OlmsteadDirector
- Andrew MillerDirector
- William WiesmannExecutive Officer, Director
- Offering amount
- $6.5M
- Amount sold
- $6M
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.5MraisedMar 2015 · 1 investors · PharmaceuticalsRule 506(b)
▶$3.5MraisedMar 2015 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Clarke AtwellDirector
- Larry ShapiroDirector
- William WiesmannExecutive Officer, Director
- Kenton GregoryDirector
- Diane OlmsteadDirector
- Andrew MillerDirector
- Shenda BakerExecutive Officer, Director
- Offering amount
- $4M
- Amount sold
- $3.5M
- First sale
- Feb 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$607.4KraisedAug 2014 · 15 investors · PharmaceuticalsRule 506(b)
▶$607.4KraisedAug 2014 · 15 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Clarke AtwellDirector
- Andrew W. MillerDirector
- Shenda BakerExecutive Officer, Director
- Kenton GregoryDirector
- Larry ShapiroDirector
- Diane OlmsteadDirector
- Offering amount
- $607.4K
- Amount sold
- $607.4K
- First sale
- Aug 2014
- Incorporated
- Corporation, Delaware, 2009
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlap
Biogen Idec17 shared keywordsBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.
Solugen15 shared keywordsSolugen develops a biomanufacturing platform using fermentation and bioprocessing technology to produce specialty chemicals at scale. The company serves customers in energy, chemicals, and related industries with cost-effective alternatives to traditional petrochemical-based manufacturing.
NervGen Pharma11 shared keywordsNervGen is a clinical-stage biotech company developing therapies for neurological conditions, with a focus on spinal cord injury and neurorepair. It maintains a drug pipeline and operates as a publicly traded company.
PepGen11 shared keywordsPepGen is a clinical-stage biotech company developing oligonucleotide therapies for neuromuscular and neurological diseases using its Enhanced Delivery Oligonucleotide (EDO) platform to improve tissue penetration and uptake in muscle tissues.
Urogen10 shared keywordsUroGen is a biotech company developing treatments for urothelial and specialty cancers using a proprietary sustained-release hydrogel platform technology. The company commercializes approved therapies for bladder and upper tract cancers, with additional candidates in development.
Amgen9 shared keywordsAmgen develops therapies based on biotechnology and scientific research aimed at treating patients and improving or saving lives. It operates in the biopharmaceutical industry, moving discoveries from the laboratory through clinical development to market.
Companies competing with Synedgen for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 10 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| Department of DefenseDefense Health Program | Phase II | 2020 | $1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $224.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $146.4K |
| Department of DefenseDefense Health Program | Phase II | 2014 | $870.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $196.7K |
| Department of DefenseDefense Health Program | Phase I | 2013 | $149.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2013 | $149.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2011 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2010 | $99.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2009 | $99.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Synedgen do?
- Synedgen develops first-in-class glycomics-based regenerative therapeutics that repair mucosal injury and restore barrier function. Its lead asset, MIIST305, is an orally delivered therapeutic that repairs gastrointestinal mucosal injury and reduces inflammation.
- Who founded Synedgen?
- Synedgen was founded by Shenda Baker, William P. Wiesmann in 2009.
- How much funding has Synedgen raised?
- Synedgen has disclosed $20.4M raised across 7 rounds.
- Where is Synedgen headquartered?
- Synedgen is headquartered in Claremont, US.